Index RUT P/E - EPS (ttm) -1.53 Insider Own 65.43% Shs Outstand 161.71M Perf Week -7.89%
Market Cap 226.77M Forward P/E - EPS next Y -1.23 Insider Trans -0.14% Shs Float 56.00M Perf Month -16.17%
Income -243.79M PEG - EPS next Q -0.38 Inst Own 37.28% Short Float 21.93% Perf Quarter -86.50%
Sales 0.00M P/S - EPS this Y 4.29% Inst Trans 15.63% Short Ratio 3.74 Perf Half Y -87.60%
Book/sh 1.78 P/B 0.79 EPS next Y 15.74% ROA -59.96% Short Interest 12.28M Perf Year -92.24%
Cash/sh 1.91 P/C 0.73 EPS next 5Y 8.30% ROE -64.48% 52W Range 1.26 - 17.19 Perf YTD -86.79%
Dividend Est. - P/FCF - EPS past 5Y - ROI -84.92% 52W High -91.85% Beta 2.14
Dividend TTM - Quick Ratio 10.51 Sales past 5Y 0.00% Gross Margin - 52W Low 11.11% ATR (14) 0.17
Dividend Ex-Date - Current Ratio 10.51 EPS Y/Y TTM -0.42% Oper. Margin - RSI (14) 29.78 Volatility 11.63% 8.45%
Employees 110 Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 2.11 Target Price 6.67
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q 46.63% Payout - Rel Volume 0.45 Prev Close 1.38
Sales Surprise - EPS Surprise 12.74% Sales Q/Q - Earnings Mar 03 BMO Avg Volume 3.28M Price 1.40
SMA20 -10.36% SMA50 -36.76% SMA200 -84.72% Trades
Volume 1,468,554 Change 1.45%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-10-25 Downgrade William Blair
Outperform → Mkt Perform
Mar-07-25 Downgrade Stifel
Buy → Hold
$6 → $2
Mar-07-25 Downgrade Guggenheim
Buy → Neutral
Jan-02-25 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$29 → $4
Nov-05-24 Downgrade JP Morgan
Overweight → Neutral
$18 → $15
Oct-01-24 Initiated H.C. Wainwright
Buy
$30
Jul-22-24 Initiated Needham
Buy
$23
Jul-08-24 Initiated Mizuho
Outperform
$20
Dec-12-23 Initiated Deutsche Bank
Hold
$13
Oct-10-23 Initiated William Blair
Outperform
$26
Oct-10-23 Initiated Stifel
Buy
$26
Oct-10-23 Initiated RBC Capital Mkts
Outperform
$24
Oct-10-23 Initiated JP Morgan
Overweight
$21
Oct-10-23 Initiated Guggenheim
Buy
$22
Oct-10-23 Initiated BofA Securities
Buy
$18
Show Previous Ratings
Mar-07-25 12:26PM
07:08AM
Mar-04-25 08:30AM
06:25AM
Mar-03-25 07:00AM
05:45AM
Loading…
Feb-28-25 05:45AM
Feb-26-25 08:46PM
Feb-25-25 05:45AM
Feb-18-25 05:45AM
Feb-13-25 10:33AM
07:00AM
Feb-11-25 05:45AM
Jan-04-25 08:00AM
Jan-03-25 07:20AM
Jan-02-25 05:07PM
04:22PM
Loading…
04:22PM
(Investor's Business Daily)
01:28PM
01:07PM
(Pharmaceutical Technology)
12:00PM
10:47AM
09:59AM
09:54AM
08:30AM
07:00AM
Nov-19-24 08:53AM
Nov-12-24 07:00AM
Nov-06-24 07:00AM
Oct-29-24 07:00AM
Aug-14-24 07:00AM
Aug-06-24 01:54PM
07:00AM
Loading…
07:00AM
Jul-01-24 01:00AM
Jun-20-24 07:00AM
May-14-24 08:52AM
07:00AM
May-07-24 01:54PM
10:20AM
07:00AM
May-06-24 07:00AM
Apr-16-24 11:28AM
Apr-15-24 04:20PM
(Investor's Business Daily) -17.48%
12:17PM
08:45AM
07:47AM
06:36AM
06:30AM
Mar-13-24 07:00AM
Mar-07-24 02:52PM
07:00AM
Jan-22-24 07:00AM
Jan-10-24 08:32AM
Jan-02-24 07:00AM
Dec-17-23 12:35PM
Dec-12-23 07:00AM
Nov-27-23 07:00AM
Nov-01-23 07:00AM
Oct-30-23 07:00AM
Oct-10-23 07:00AM
Sep-28-23 07:54PM
(InvestorPlace) +11.84%
+6.73%
Sep-27-23 06:50PM
Sep-18-23 12:35PM
Sep-14-23 08:49PM
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Henry Gosebruch Officer Mar 12 '25 Proposed Sale 1.43 15,000 21,450 Mar 12 04:49 PM BERNS PAUL L See Remarks Feb 18 '25 Sale 1.69 13,871 23,468 7,405,004 Feb 20 05:14 PM Milligan Michael Lee See Remarks Feb 18 '25 Sale 1.69 1,978 3,351 22,470 Feb 20 05:14 PM Aurora Daljit Singh Chief Strategy Officer Feb 18 '25 Sale 1.68 8,565 14,347 88,935 Feb 20 05:13 PM Lenz Robert A. Head of R&D Feb 18 '25 Sale 1.67 5,614 9,383 309,092 Feb 20 05:12 PM Pinto Joshua President Feb 18 '25 Sale 1.67 8,048 13,477 76,952 Feb 20 05:11 PM Suh Carol Y. Officer Feb 18 '25 Proposed Sale 1.68 9,540 16,020 Feb 18 05:51 PM Milligan Michael Lee Officer Feb 18 '25 Proposed Sale 1.69 1,978 3,351 Feb 18 05:49 PM Pinto Joshua Officer Feb 18 '25 Proposed Sale 1.67 8,048 13,478 Feb 18 05:45 PM Lenz Robert A. Officer Feb 18 '25 Proposed Sale 1.67 5,614 9,383 Feb 18 05:43 PM Gosebruch Henry O Officer Feb 18 '25 Proposed Sale 1.67 6,857 11,462 Feb 18 05:41 PM BERNS PAUL L Officer Feb 18 '25 Proposed Sale 1.69 13,871 23,468 Feb 18 05:40 PM Aurora Daljit Singh Officer Feb 18 '25 Proposed Sale 1.68 8,565 14,348 Feb 18 05:38 PM Fust Matthew K Director Oct 18 '24 Option Exercise 5.29 14,049 74,309 34,149 Oct 18 06:25 PM Fust Matthew K Director Oct 17 '24 Option Exercise 6.81 7,739 52,730 27,839 Oct 18 06:25 PM Fust Matthew K Director Oct 18 '24 Sale 17.03 14,049 239,319 20,100 Oct 18 06:25 PM Fust Matthew K Director Oct 17 '24 Sale 17.01 7,739 131,643 20,100 Oct 18 06:25 PM Fust Matthew K Director Oct 18 '24 Proposed Sale 17.03 14,049 239,319 Oct 18 04:01 PM Fust Matthew K Director Oct 17 '24 Proposed Sale 17.01 7,739 131,643 Oct 17 04:26 PM Lenz Robert A. Head of R&D Oct 10 '24 Sale 15.09 8,260 124,603 314,706 Oct 11 04:10 PM Lenz Robert A. Head of R&D Oct 09 '24 Sale 15.01 5,563 83,507 322,966 Oct 11 04:10 PM Lenz Robert A. Officer Oct 10 '24 Proposed Sale 15.09 8,260 124,603 Oct 10 04:30 PM Lenz Robert A. Officer Oct 09 '24 Proposed Sale 15.01 5,563 83,507 Oct 09 04:10 PM Lenz Robert A. Head of R&D Sep 17 '24 Sale 11.81 30,788 363,736 339,205 Sep 19 04:35 PM Lenz Robert A. Head of R&D Sep 18 '24 Sale 12.09 10,676 129,091 328,529 Sep 19 04:35 PM Lenz Robert A. Officer Sep 18 '24 Proposed Sale 12.09 10,676 129,091 Sep 18 04:27 PM Lenz Robert A. Officer Sep 17 '24 Proposed Sale 11.81 30,788 363,734 Sep 17 04:37 PM Lenz Robert A. Head of R&D Sep 12 '24 Sale 11.43 32,948 376,665 369,993 Sep 16 04:05 PM Lenz Robert A. Officer Sep 12 '24 Proposed Sale 11.43 32,948 376,665 Sep 12 05:18 PM Pinto Joshua Chief Financial Officer Aug 27 '24 Sale 11.39 15,693 178,806 138,965 Aug 27 05:58 PM Pinto Joshua Chief Financial Officer Aug 26 '24 Sale 11.78 31,642 372,588 154,658 Aug 26 06:17 PM Pinto Joshua Chief Financial Officer Aug 22 '24 Sale 11.63 28,496 331,468 210,469 Aug 26 06:17 PM Pinto Joshua Chief Financial Officer Aug 23 '24 Sale 11.59 24,169 280,005 186,300 Aug 26 06:17 PM Pinto Joshua Officer Aug 22 '24 Proposed Sale 11.90 100,000 1,190,000 Aug 22 09:48 AM
Index - P/E - EPS (ttm) - Insider Own 42.97% Shs Outstand 103.04M Perf Week -9.88%
Market Cap 2.56B Forward P/E - EPS next Y -3.28 Insider Trans 13.08% Shs Float 60.07M Perf Month -21.13%
Income - PEG - EPS next Q -0.87 Inst Own 1.76% Short Float 6.99% Perf Quarter -
Sales - P/S - EPS this Y 35.03% Inst Trans 39.17% Short Ratio 5.85 Perf Half Y -
Book/sh -0.44 P/B - EPS next Y -16.15% ROA - Short Interest 4.20M Perf Year -
Cash/sh 0.71 P/C 33.98 EPS next 5Y 2.70% ROE - 52W Range 23.91 - 32.81 Perf YTD -8.45%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -26.06% Beta -
Dividend TTM - Quick Ratio 3.81 Sales past 5Y 0.00% Gross Margin - 52W Low 1.46% ATR (14) 2.15
Dividend Ex-Date - Current Ratio 3.81 EPS Y/Y TTM - Oper. Margin - RSI (14) 41.79 Volatility 7.12% 7.39%
Employees - Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 47.00
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q - Payout - Rel Volume 0.83 Prev Close 25.78
Sales Surprise - EPS Surprise 0.00% Sales Q/Q - Earnings Feb 26 Avg Volume 717.45K Price 24.26
SMA20 -12.87% SMA50 -14.20% SMA200 -14.20% Trades
Volume 596,790 Change -5.90%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-25-25 Initiated Guggenheim
Buy
$56
Feb-25-25 Initiated Evercore ISI
Outperform
Feb-25-25 Initiated BofA Securities
Buy
$38
Mar-06-25 10:13AM
Mar-03-25 02:50PM
Mar-01-25 05:02AM
(Thomson Reuters StreetEvents)
Feb-26-25 07:00AM
Feb-25-25 02:04PM
02:50PM
Loading…
Feb-19-25 02:50PM
Feb-05-25 04:01PM
Jan-30-25 08:13PM
06:53PM
02:57PM
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Burow Kristina Director Feb 03 '25 Buy 18.00 2,222,222 39,999,996 18,503,128 Feb 03 07:15 PM BERNS PAUL L Director Feb 03 '25 Buy 18.00 789,998 14,219,964 8,313,680 Feb 03 07:04 PM ARCH Venture Partners XII, LLC 10% Owner Feb 03 '25 Buy 18.00 2,222,222 39,999,996 18,503,128 Feb 03 07:01 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
